Cryomass Technologies Inc
Cryomass Technologies Inc., together with its subsidiaries, develops and licenses equipment to refine harvested cannabis, hemp, and other premium crops in the United States. It offers CryoSift Separator, which capture intact cannabis and hemp trichomes. The company was formerly known as Andina Gold Corp. and changed its name to Cryomass Technologies Inc. in August 2021. Cryomass Technologies Inc.… Read more
Cryomass Technologies Inc (CRYM) - Net Assets
Latest net assets as of September 2024: $-9.44 Million USD
Based on the latest financial reports, Cryomass Technologies Inc (CRYM) has net assets worth $-9.44 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.13 Million) and total liabilities ($10.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.44 Million |
| % of Total Assets | -835.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | -142.59% |
| 10-Year Change | N/A |
| Growth Volatility | 835.35 |
Cryomass Technologies Inc - Net Assets Trend (2017–2023)
This chart illustrates how Cryomass Technologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cryomass Technologies Inc (2017–2023)
The table below shows the annual net assets of Cryomass Technologies Inc from 2017 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-5.85 Million | -227.87% |
| 2022-12-31 | $4.57 Million | -66.18% |
| 2021-12-31 | $13.52 Million | +275.12% |
| 2020-12-31 | $3.61 Million | -73.75% |
| 2019-12-31 | $13.73 Million | +2024.32% |
| 2018-12-31 | $646.53K | +465.13% |
| 2017-12-31 | $-177.07K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cryomass Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5155405700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $46.12 Million | % |
| Total Equity | $-5.85 Million | 100.00% |
Cryomass Technologies Inc Competitors by Market Cap
The table below lists competitors of Cryomass Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Finnovate Acquisition Corp. Warrants
NASDAQ:FNVTW
|
$47.46K |
|
Anderson Energy Inc
F:8DA1
|
$47.46K |
|
Bee Vectoring Technologies International Inc
PINK:BEVVF
|
$47.51K |
|
EUROPEAN MEDICAL SOLUTIONS
BR:ALEMS
|
$47.53K |
|
MINT Income Fund
TO:MID-UN
|
$47.43K |
|
Manhattan Scients
PINK:MHTX
|
$47.42K |
|
TEND3F
SA:TEND3F
|
$47.40K |
|
Sayward Capital Corp
V:SAWC-P
|
$47.35K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cryomass Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,574,468 to -5,849,242, a change of -10,423,710 (-227.9%).
- Net loss of 12,955,728 reduced equity.
- New share issuances of 387,642 increased equity.
- Other factors increased equity by 2,144,376.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.96 Million | -221.49% |
| Share Issuances | $387.64K | +6.63% |
| Other Changes | $2.14 Million | +36.66% |
| Total Change | $- | -227.87% |
Book Value vs Market Value Analysis
This analysis compares Cryomass Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $0.03 | x |
| 2018-12-31 | $0.01 | $0.03 | x |
| 2019-12-31 | $0.12 | $0.03 | x |
| 2020-12-31 | $0.04 | $0.03 | x |
| 2021-12-31 | $0.07 | $0.03 | x |
| 2022-12-31 | $0.02 | $0.03 | x |
| 2023-12-31 | $-0.03 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cryomass Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -95600.12%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-105.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.06K |
| 2018 | -66.12% | 0.00% | 0.00x | 1.09x | $-492.11K |
| 2019 | -24.58% | -87.89% | 0.22x | 1.29x | $-4.30 Million |
| 2020 | -327.74% | -1512.04% | 0.10x | 2.16x | $-12.18 Million |
| 2021 | -95.09% | 0.00% | 0.00x | 1.15x | $-14.21 Million |
| 2022 | -227.84% | 0.00% | 0.00x | 1.72x | $-10.88 Million |
| 2023 | 0.00% | -95600.12% | 0.01x | 0.00x | $-12.37 Million |
Industry Comparison
This section compares Cryomass Technologies Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cryomass Technologies Inc (CRYM) | $-9.44 Million | 0.00% | N/A | $47.43K |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |